|
Druggable Formulation for Mu/Delta Opioid Antagonist for Enhancing Pain Therapy and Treatment of Opioid Withdrawal
This invention provides compositions and method of pain treatment using a mu/delta opioid receptor heterodimer (MDOR) antagonist which has improved druggability by nanoformulation and/or glycosylation to increase their bioavailability and efficacy. These modified antagonists and formulations provide for enhancement of opioid agonist therapy's antinociceptive...
Published: 3/12/2024
|
Inventor(s): John Streicher, Robin Polt, Lajos Szabo, Wafaa Alabsi, Parthasaradhi Reddy Tanguturi
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Neurology
|
|
Small Molecule Mixed Agonist/Antagonist for Opioid Receptors for Anti-Addiction and/or Pain Therapy
This invention provides compositions and method of pain treatment using a mixture of an opioid receptor agonist in combination with an adrenoreceptor modulator compound. The opioid receptor agonist may be a clinically-used drug, and the adrenoreceptor modulator compound is a novel small molecule. Proof-of-concept testing in animals has shown...
Published: 3/12/2024
|
Inventor(s): Iman Daryaei, John Streicher, Abigail Schwarz
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Novel Peptides Bioavailable to the Brain for Non-Opioid Pain Relief and/or Addiction Treatment
Inventors at the University of Arizona have developed oxytocin analogues which have high potency, are designed to be more stable compared to the native oxytocin hormone (an endogenous peptide which inhibits pain and promotes social connection), have very high selectivity for oxytocin receptors, and are bioavailable for brain therapeutics. These druggable...
Published: 3/12/2024
|
Inventor(s): Lajos Szabo, Robin Polt, John Streicher, Michael Heien, Parthasaradhi Reddy Tanguturi
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences, Technology Classifications > Healthcare Portfolios > Neurology > Mental Health, Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Glycopeptide and Classical Drug Design
This invention relates to the glycosylation drug candidates to increase penetration, bioavailability, and stability.
Background:
Transmembrane proteins provide a pathway for drugs to interact with a cell's interior. Drugs commonly target G-protein coupled receptors (GPCRs), comprising 40% of the market. Peptides and small molecule drugs directed...
Published: 3/12/2024
|
Inventor(s): Robin Polt, Christopher Apostol, Michael Heien, Chenxi Liu, John Streicher, Lajos Szabo, Torsten Falk
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences, Technology Classifications > Life Sciences > Drug Delivery
|
|
Glycosylation of Secretin Peptides to Improve Drug-Like Properties
This invention is the development of pituitary adenylate cyclase activating peptide (PACAP) agonists for neuroprotection and antagonists for migraine.
Background:
PACAP is known as a neuronal survival factor, regulating the development, maintenance, function, and plasticity of neurons through activating PAC1, VPAC1, and VPAC2 receptors. Glycosylated...
Published: 3/12/2024
|
Inventor(s): Robin Polt, Evan Jones, Bobbi Anglin, Michael Heien, John Streicher
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences
|
